Lenox Wealth Advisors’s Novavax NVAX Stock Holding History

Lenox Wealth Advisors’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-4	Closed	-$1K	–	922
2021 Q4	$1K	Buy	+4	New	+$687	﹤0.01%	881

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Lenox Wealth Advisors's NVAX Position: Q1 2022 in Review

Lenox Wealth Advisors sold out of Novavax (NVAX) in Q1 2022, closing a stake of 4 shares — an estimated $1K sold.

Lenox Wealth Advisors first reported a position in NVAX in Q4 2021 and held it in 1 quarter. The position peaked at $1K in Q4 2021. 380 funds tracked by Wall St. Rank hold NVAX as of Q1 2022.

Lenox Wealth Advisors reported no remaining Novavax position as of Q1 2022 after selling out during the quarter.
Lenox Wealth Advisors sold 4 Novavax shares in Q1 2022, an estimated $1K.
Lenox Wealth Advisors first reported a position in Novavax in Q4 2021 and held it in 1 quarter.
Lenox Wealth Advisors's Novavax position peaked at $1K in Q4 2021.
380 funds tracked by Wall St. Rank held Novavax as of Q1 2022.

Based on Lenox Wealth Advisors's 13F filing for Q1 2022, filed 14 Apr 2022.